Dr. Fleshner's clinical practice is in urologic oncology with research interests in prostate and bladder cancer.
Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
Eur Urol Oncol. 2018 Aug;1(3):238-241
Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
PLoS One. 2019;14(4):e0216255
Mol Metab. 2019 Apr 10;:
Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer.
Eur Urol Oncol. 2019 Feb;2(1):88-96
Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Clin Epigenetics. 2019 03 27;11(1):54
Pfilates and Hypopressives for the Treatment of Urinary Incontinence after Radical Prostatectomy: Results of a Feasibility Randomized Controlled Trial.
PM R. 2019 Mar 14;:
J Urol. 2019 Mar 13;:101097JU0000000000000213
Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A....
J Urol. 2018 05;199(5):1354-1355
JCO Precis Oncol. 2019;2019:
Martin Barkin Chair, Division of Urology, Department of Surgery, University of Toronto
Professor, Department of Surgery, University of Toronto